Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for
therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 …

Simple Summary A rapidly emerging new approach to treat cancer involves collection of
patient immune white blood cells and genetic re-programming of the cells to express a new …

As genetically engineered cells, chimeric antigen receptor (CAR)-T cells express specific
receptors on their surface to target and eliminate malignant cells. CAR proteins are …

Chimeric antigen receptor (CAR) T cells have transformed the treatment landscape for
hematological malignancies. However, CAR T cells are less efficient against solid tumors …

Therapy employing T cells modified with chimeric antigen receptors (CARs) is effective in
hematological malignancies but not yet in solid cancers. CAR T cell activity in solid tumors is …

Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as
promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific …

Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first
identified in advanced prostate cancer, its overexpression is recognized in multiple types of …

Simple Summary In the present study, we addressed the unmet need for a molecular
antibody (mAb) with high affinity and specificity against a truncated hyperactive isoform of …

We have developed a chimeric antigen receptor (CAR) against the six-transmembrane
epithelial antigen of prostate-1 (STEAP1), which is expressed in prostate cancer, Ewing …

Immunotherapy with checkpoint inhibitors alone or in combination with a variety of agents
such as chemotherapy, poly-ADP ribose polymerase (PARP) inhibitors or novel biologics …